Peapack Gladstone Financial Corp Sells 28,011 Shares of Pfizer Inc. (NYSE:PFE)

Peapack Gladstone Financial Corp lessened its stake in Pfizer Inc. (NYSE:PFE) by 3.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 734,965 shares of the biopharmaceutical company’s stock after selling 28,011 shares during the period. Peapack Gladstone Financial Corp’s holdings in Pfizer were worth $19,499,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer during the fourth quarter valued at $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer during the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the 4th quarter valued at about $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer during the fourth quarter worth approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $22.99 on Friday. The company has a fifty day moving average price of $25.87 and a 200 day moving average price of $26.74. The firm has a market cap of $130.39 billion, a PE ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1-year low of $22.95 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the firm earned $0.10 earnings per share. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on PFE shares. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Citigroup reissued a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.